| Overview |
| bs-12083R-Cy5 |
| GABRQ/GABA A Receptor theta Antibody, Cy5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Rabbit |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human GABRQ/GABA A Receptor ta |
| 211-320/632 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cell membrane |
| gamma aminobutyric acid GABA receptor, theta; Gamma aminobutyric acid receptor theta subunit precursor; gamma aminobutyric acid receptor, theta; THETA; GBRT_HUMAN. |
| Gamma-aminobutyric acid type A (GABAA) receptors mediate inhibitory neurotransmission in the mammalian central nervous system. The receptor exists as a pentameric ion channel composed by heteromeric combinations of alpha, beta, gamma, delta, epsilon, theta, or pi subunits. Only specific subunit combinations produce viable receptors, while others never translocate to the cell surface from the ER where they are synthesized, and subsequently degraded. The theta subunit forms a receptor in combination with alpha3 subunits in monoaminergic cell groups. These receptors, found especially in the septum, preoptic areas, hypothalamic nuclei, amygdala and thalamus, likely have unique pharmacological properties linked to their expression in this particular cell type and not cholinergic cell groups, and may play a role in opiate withdrawl symptoms. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz